According to the Cancer Genome Atlas, ACSL3 expression is reported to be 8% lower in GBM than in non-tumor cells. Poorer clinical outcomes have been linked to ACSL3 overexpression in patients with high-grade NSCLC [39]. This evidence concerns the gene ACSL3 and neoplasm.